Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1149

1.

Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.

Zou M, Xia S, Zhuang L, Han N, Chu Q, Chao T, Peng P, Chen Y, Gui Q, Yu S.

Int J Oncol. 2013 Jun;42(6):2094-102. doi: 10.3892/ijo.2013.1895. Epub 2013 Apr 12.

PMID:
23588221
2.

Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.

Yun M, Kim EO, Lee D, Kim JH, Kim J, Lee H, Lee J, Kim SH.

Cell Physiol Biochem. 2014;34(3):865-72. doi: 10.1159/000366305. Epub 2014 Aug 21.

3.

Gefitinib analogue V1801 induces apoptosis of T790M EGFR-harboring lung cancer cells by up-regulation of the BH-3 only protein Noxa.

Zhang B, Jiao J, Liu Y, Guo LX, Zhou B, Li GQ, Yao ZJ, Zhou GB.

PLoS One. 2012;7(11):e48748. doi: 10.1371/journal.pone.0048748. Epub 2012 Nov 21.

4.
5.

Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.

Hwang KE, Kwon SJ, Kim YS, Park DS, Kim BR, Yoon KH, Jeong ET, Kim HR.

Exp Cell Res. 2014 May 1;323(2):288-96. doi: 10.1016/j.yexcr.2014.02.026. Epub 2014 Mar 12.

PMID:
24631288
6.

Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.

Yoshida T, Okamoto I, Okamoto W, Hatashita E, Yamada Y, Kuwata K, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.

Cancer Sci. 2010 Jan;101(1):167-72. doi: 10.1111/j.1349-7006.2009.01368.x. Epub 2009 Sep 14.

7.

244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.

Zhang Y, Yao K, Shi C, Jiang Y, Liu K, Zhao S, Chen H, Reddy K, Zhang C, Chang X, Ryu J, Bode AM, Dong Z, Dong Z.

Oncotarget. 2015 Dec 29;6(42):44274-88. doi: 10.18632/oncotarget.6236.

8.

Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.

Lee JY, Lee YM, Chang GC, Yu SL, Hsieh WY, Chen JJ, Chen HW, Yang PC.

PLoS One. 2011;6(8):e23756. doi: 10.1371/journal.pone.0023756. Epub 2011 Aug 17.

9.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
10.

Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.

Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S, Yano S.

Clin Cancer Res. 2010 Jan 1;16(1):174-83. doi: 10.1158/1078-0432.CCR-09-1204. Epub 2009 Dec 15.

11.

Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.

Minakata K, Takahashi F, Nara T, Hashimoto M, Tajima K, Murakami A, Nurwidya F, Yae S, Koizumi F, Moriyama H, Seyama K, Nishio K, Takahashi K.

Cancer Sci. 2012 Nov;103(11):1946-54. doi: 10.1111/j.1349-7006.2012.02408.x. Epub 2012 Sep 14.

12.

Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.

Han SY, Zhao MB, Zhuang GB, Li PP.

Lung Cancer. 2012 Jan;75(1):30-7. doi: 10.1016/j.lungcan.2011.06.001. Epub 2011 Jul 16.

PMID:
21757251
13.

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.

Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S.

PLoS Med. 2007 Oct;4(10):1669-79; discussion 1680.

14.

Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.

Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S.

Mol Cancer Ther. 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. Epub 2012 Jul 25.

15.

Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.

Wang M, Zhao J, Zhang LM, Li H, Yu JP, Ren XB, Wang CL.

J Cancer Res Clin Oncol. 2012 Dec;138(12):2069-77. doi: 10.1007/s00432-012-1291-2. Epub 2012 Jul 22.

PMID:
22821179
16.

Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.

Choi YJ, Rho JK, Jeon BS, Choi SJ, Park SC, Lee SS, Kim HR, Kim CH, Lee JC.

Cancer Chemother Pharmacol. 2010 Jul;66(2):381-8. doi: 10.1007/s00280-009-1174-7. Epub 2009 Nov 18.

PMID:
19921194
17.

Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.

Xie M, He CS, Wei SH, Zhang L.

Eur J Cancer. 2013 Nov;49(16):3559-72. doi: 10.1016/j.ejca.2013.07.007. Epub 2013 Aug 2.

PMID:
23916913
18.

Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.

Li XY, Wu JZ, Cao HX, Ma R, Wu JQ, Zhong YJ, Feng JF.

Oncol Rep. 2013 May;29(5):1975-82. doi: 10.3892/or.2013.2298. Epub 2013 Feb 21.

PMID:
23440266
19.

Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation.

Zhao BX, Wang J, Song B, Wei H, Lv WP, Tian LM, Li M, Lv S.

Mol Med Rep. 2015 Apr;11(4):2767-74. doi: 10.3892/mmr.2014.3058. Epub 2014 Dec 8.

PMID:
25483995
20.

Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations.

Yamada T, Takeuchi S, Fujita N, Nakamura A, Wang W, Li Q, Oda M, Mitsudomi T, Yatabe Y, Sekido Y, Yoshida J, Higashiyama M, Noguchi M, Uehara H, Nishioka Y, Sone S, Yano S.

Oncogene. 2013 Sep 12;32(37):4427-35. doi: 10.1038/onc.2012.446. Epub 2012 Oct 8.

PMID:
23045273

Supplemental Content

Support Center